TriSalus Life Sciences Announces Late Breaker and Additional Data Presentations on Liver Metastases and Pancreatic Cancer at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting
25 Octubre 2023 - 8:05AM
Business Wire
TriSalus Life Sciences® Inc., (Nasdaq: TLSI), an oncology
company integrating its novel delivery technology with
immunotherapy to transform treatment for patients with liver and
pancreatic tumors, today announced it will present a variety of new
data from its innovative clinical development pipeline at the
Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
being held November 1-5, 2023, in San Diego, California.
Presentation details for SITC 2023 are as follows:
Late Breaker Oral Presentation:
Clinical Activity of SD-101 with Immune Checkpoint Inhibition (ICI)
in Metastatic Uveal Melanoma Liver Metastasis (MUM-LM) from the
PERIO-01 Phase 1 Trial Presenter: Sapan P. Patel, M.D.,
Director of the Uveal Melanoma Program, The University of Texas MD
Anderson Cancer Center Abstract: 1534 Session:
Late-Breaking Abstract Session Time: Saturday, November 4,
11:25 a.m. PDT Poster Presentation also available in the Poster
Hall and in the Virtual ePoster Hall
Poster Presentation: PERIO-03:
Pressure Enabled Intrapancreatic Delivery of SD-101 with Checkpoint
Blockade for Locally Advanced Pancreatic Adenocarcinoma – Initial
Safety and Feasibility Experience Abstract: 647
Presenter: Michael S. Lee, M.D., Associate Professor, The
University of Texas MD Anderson Cancer Center Time: Friday,
November 3, 9:00 a.m. – 7:00 p.m. PDT
Poster Presentation: Checkpoint
Inhibitor Administered Either Systemically of Subcutaneously
Enhances the Anti-Tumor Immunity of SD-101 Delivered by
Pressure-enabled Drug Delivery (PEDD) Device in Treating Liver
Metastasis (LM) Abstract: 1123 Presenter: Chandra C.
Ghosh, Ph.D., TriSalus Life Sciences Time: Friday, November
3, 9:00 a.m. – 7:00 p.m. PDT
The presentations will be available here following their
respective sessions.
About TriSalus Life Sciences
TriSalus Life Sciences® is an oncology company integrating novel
delivery technology with immunotherapy to transform treatment for
patients with liver and pancreatic tumors.
The Company’s platform includes devices that utilize a
proprietary drug delivery technology and a clinical stage
investigational immunotherapy. The Company’s two FDA-cleared
devices use its proprietary Pressure-Enabled Drug Delivery™ (PEDD)
approach to deliver a range of therapeutics: the TriNav® Infusion
System for hepatic arterial infusion of liver tumors and the
Pancreatic Retrograde Venous Infusion System for pancreatic tumors.
PEDD is a novel delivery approach designed to address the anatomic
limitations of arterial infusion for the pancreas. The PEDD
approach modulates pressure and flow in a manner that delivers more
therapeutic to the tumor and is designed to reduce undesired
delivery to normal tissue, bringing the potential to improve
patient outcomes. SD-101, the Company’s investigational
immunotherapeutic candidate, is designed to improve patient
outcomes by treating the immunosuppressive environment created by
many tumors and which can make current immunotherapies ineffective
in the liver and pancreas. Patient data generated during
Pressure-Enabled Regional Immuno-Oncology™ (PERIO) clinical trials
support the hypothesis that SD-101 delivered via PEDD may have
favorable immune effects within the liver and systemically. The
target for SD-101, TLR9, is expressed across cancer types and the
mechanical barriers addressed by PEDD are commonly present as well.
SD-101 delivered by PEDD will be studied across several indications
in an effort to address immune dysfunction and overcome drug
delivery barriers in the liver and pancreas.
In partnership with leading cancer centers across the country –
and by leveraging deep immuno-oncology expertise and inventive
technology development – TriSalus is committed to advancing
innovation that improves outcomes for patients. Learn more at
trisaluslifesci.com and follow us on Twitter and LinkedIn.
Forward Looking Statements
Statements made in this press release regarding matters that are
not historical facts are “forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995.
Because such statements are subject to risks and uncertainties,
actual results may differ materially from those expressed or
implied by such forward‐looking statements. Such statements
include, but are not limited to, statements regarding the benefits
and potential benefits of the Company’s PEDD drug delivery
technology and SD-101 investigational immunotherapy. Risks that
could cause actual results to differ from those expressed in these
forward‐looking statements include risks associated with clinical
development and regulatory approval of drug delivery and
pharmaceutical product candidates, including that future clinical
results may not be consistent with patient data generated during
the Company’s PERIO clinical trials, and other risks described in
the Company’s filings with the Securities and Exchange Commission
under the heading “Risk Factors.” All forward‐looking statements
contained in this press release speak only as of the date on which
they were made and are based on management’s assumptions and
estimates as of such date. The Company undertakes no obligation to
update such statements to reflect events that occur or
circumstances that exist after the date on which they were made
except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231025508206/en/
For Media and Investor Inquiries: Argot Partners
212.600.1902 TriSalus@argotpartners.com
TriSalus Life Sciences (NASDAQ:TLSI)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
TriSalus Life Sciences (NASDAQ:TLSI)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024